No Prescription |
 |
 | ||
|
VENTOLIN INHALER Ventorlin |
|
| ||
No Prescription » Prescription Drugs 17 » VENTOLIN INHALER Ventorlin Chemical Name: ALBUTEROL (al-BYOO-ter-ole) Bronchodilators to treat chronic asthma chronic obstructive pulmonary disorders.Treating or preventing breathing problems in patients who have asthma or certain other airway diseases. It may be used to prevent breathing problems caused by exercise. Ventolin inhaler is used to prevent and treat wheezing shortness of breath and troubled breathing caused by asthma chronic bronchitis emphysema and other lung diseases. It works by relaxing and opening air passages in the lungs making it easier to breathe. SIDE EFFECTS that may occur while taking this medication includes tremor nervousness shakiness dizziness excitement headache difficulty falling asleep or staying asleep nose bleed increased appetite upset stomach vomiting stomach pain muscle cramps cough dry mouth and throat irritation. Buy VENTOLIN INHALER Ventorlin and other Prescription Drugs 17 products online at Medstore. 3578
About VENTOLIN INHALER Ventorlin: Product Type: Prescription Drugs 17 VENTOLIN INHALER ( Ventorlin Proventil Generic Albuterol/Salbutamol ) VENTOLIN INHALER (Ventorlin Proventil Generic Albuterol/Salbutamol) Ventorlin Proventil Generic Albuterol/Salbutamol 100mcg 200 dose inhaler Ventorlin Proventil Generic Albuterol/Salbutamol VENTOLIN INHALER
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
